Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 3 | 2023 | 166 | 0.560 |
Why?
|
| Genetic Therapy | 2 | 2009 | 118 | 0.380 |
Why?
|
| Genetic Vectors | 2 | 2009 | 127 | 0.330 |
Why?
|
| Lentivirus | 1 | 2009 | 17 | 0.330 |
Why?
|
| Skin | 2 | 2009 | 417 | 0.320 |
Why?
|
| Fibroblasts | 1 | 2009 | 354 | 0.280 |
Why?
|
| Palliative Care | 2 | 2023 | 188 | 0.230 |
Why?
|
| Terminal Care | 1 | 2023 | 46 | 0.200 |
Why?
|
| Burns, Inhalation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Plant Oils | 1 | 2017 | 16 | 0.140 |
Why?
|
| Burns, Chemical | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cannabis | 1 | 2017 | 141 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2023 | 284 | 0.090 |
Why?
|
| Dermis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Mammaplasty | 1 | 2010 | 44 | 0.090 |
Why?
|
| Gene Expression | 2 | 2009 | 613 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 68 | 0.080 |
Why?
|
| 3T3 Cells | 1 | 2009 | 56 | 0.080 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2009 | 34 | 0.080 |
Why?
|
| Sutures | 1 | 2009 | 39 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2009 | 89 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2009 | 59 | 0.080 |
Why?
|
| Ischemia | 1 | 2009 | 153 | 0.070 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 3 | 0.070 |
Why?
|
| HIV-1 | 1 | 2007 | 53 | 0.070 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 28 | 0.070 |
Why?
|
| Cell Line | 1 | 2009 | 1010 | 0.070 |
Why?
|
| Humans | 9 | 2023 | 50389 | 0.060 |
Why?
|
| Burn Units | 1 | 2023 | 9 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1035 | 0.050 |
Why?
|
| Pain Management | 1 | 2023 | 172 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 2414 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6223 | 0.050 |
Why?
|
| Child | 2 | 2023 | 6877 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 374 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 1017 | 0.040 |
Why?
|
| Mice | 1 | 2009 | 5688 | 0.040 |
Why?
|
| Adult | 3 | 2023 | 13568 | 0.040 |
Why?
|
| Butanes | 1 | 2017 | 2 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 6475 | 0.030 |
Why?
|
| Animals | 2 | 2009 | 13173 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2017 | 161 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 135 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 205 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4064 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1426 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1258 | 0.020 |
Why?
|
| Seroma | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cellulitis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 175 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2009 | 1 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2009 | 16 | 0.020 |
Why?
|
| Mastectomy | 1 | 2010 | 142 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 114 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 116 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 24 | 0.020 |
Why?
|
| Response Elements | 1 | 2009 | 29 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 290 | 0.020 |
Why?
|
| Dependovirus | 1 | 2009 | 102 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 354 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 900 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 934 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Virus Internalization | 1 | 2007 | 17 | 0.020 |
Why?
|
| Female | 3 | 2017 | 26981 | 0.020 |
Why?
|
| Valine | 1 | 2007 | 57 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 145 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 467 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2007 | 208 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2007 | 115 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 118 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 111 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4913 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 132 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 1589 | 0.020 |
Why?
|
| HIV Infections | 1 | 2007 | 355 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 3180 | 0.010 |
Why?
|
| Male | 2 | 2017 | 25718 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 3692 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 9590 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 12460 | 0.010 |
Why?
|